Abstract: The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth.

Abstract: The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth. In particular, the compounds comprise Formula I: or a pharmaceutically acceptable salt thereof, wherein: R1 is hydrogen or a haloalkyl group; and each R2, R3, R4, R5, R6, and R7 is, independently, hydrogen, halogen, hydroxyl, cyano, alkyl, alkenyl, alkoxy, substituted or unsubstituted aryl, heteroaryl, phosphate, phosphoramidate, amine, alkylamino, acylamino, aminoalkoxy, or alkylthio.

Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

Abstract: The disclosure generally relates to compounds, compositions, and methods for the treatment of cancer by restoring the P53 pathway signaling to repress cancer cell growth.

Abstract: The invention includes compositions comprising NSC59984 or a derivative or analog thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.

Abstract: The invention includes compositions comprising NSC59984 or a derivative or analogue thereof and a pharmaceutically acceptable carrier. The invention further includes methods of treating or preventing cancer in a subject, comprising the step of administering to the subject the compositions contemplated within the invention.

Abstract: An electric vehicle comprises a body (1-1), an electric driving device (1-2), a storage battery (1-3) and a control system (1-4), wherein the said body is provided with a wind electric power generation device (1-5), several solar panels (1-8) are provided on the top (1-6) of the body and the hood (1-7), the said solar panel (1-8) is electrically connected to the storage battery

Abstract: A cleaning system and process for removing residual toner from an imaging surface, including a primary cleaner system for removing the predominant amount of residual toner and debris and a retractable secondary agglomeration cleaning blade mounted downstream from the primary cleaner, wherein, when the blade is moved into the engaged position, the cleaning edge is engaged with the imaging surface at for shearing release of agglomerations from the imaging surface and wherein the cleaning blade is movable to the retracted position during periods in which the primary cleaner is in its operative position.

Abstract: A cleaning system and process for removing residual toner from an imaging surface, including a primary cleaner system for removing the predominant amount of residual toner and debris and a retractable secondary agglomeration cleaning blade mounted downstream from the primary cleaner, wherein, when the blade is moved into the engaged position, the cleaning edge is engaged with the imaging surface at for shearing release of agglomerations from the imaging surface and wherein the cleaning blade is movable to the retracted position during periods in which the primary cleaner is in its operative position.

Abstract: Image quality of an image generated by a xerographic or equivalent image generating process may develop non-uniform charge characteristics, in addition to other negative effects, as a result of positive over-spray, but these negative effects can be at least attenuated by exposure of the photoreceptor to fluorescent light.

Abstract: Image quality of an image generated by a xerographic or equivalent image generating process may develop non-uniform charge characteristics, in addition to other negative effects, as a result of positive over-spray, but these negative effects can be at least attenuated by exposure of the photoreceptor to fluorescent light.